Paxlovid

All articles by Paxlovid

Why COVID patients who could most benefit from Paxlovid still aren’t getting it
Why COVID patients who could most benefit from Paxlovid still aren’t getting it
Arthur Allen, KFF Health News
March 11, 2024
2:05 pm

The price is one reason Paxlovid is not reaching those who need it most. And patients who qualify for free doses often don’t realize it or know how to get them.

What older Americans need to know about taking Paxlovid
What older Americans need to know about taking Paxlovid
Judith Graham, KHN
January 18, 2023
12:00 pm

The message from infectious disease experts and geriatricians is clear: Seek treatment with antiviral therapy, which remains effective against new covid variants.

ICER: Paxlovid is worth less than initial health benefit price benchmark
ICER: Paxlovid is worth less than initial health benefit price benchmark
Jack O'Brien
December 21, 2022
3:53 pm

The revision was attributed to lower risk of hospitalization among untreated patients and lower relative reduction in hospitalization with Paxlovid.

Paxlovid has been free so far. Next year, sticker shock awaits.
Paxlovid has been free so far. Next year, sticker shock awaits.
Hannah Recht, KHN
December 7, 2022
3:00 pm

Millions of people who are at the highest risk of severe illness and are least able to afford the drug may have to pay the full price.

Pfizer’s COVID pill Paxlovid has profound effect in seniors, jury still out for younger adults
Pfizer’s COVID pill Paxlovid has profound effect in seniors, jury still out for younger adults
Marc Iskowitz
September 6, 2022
2:21 pm

What mainstream media may have overlooked about a recent Paxlovid study: patients who weren’t immunized still received benefits.

Paxlovid prescribing privileges extended to pharmacists
Paxlovid prescribing privileges extended to pharmacists
Marc Iskowitz
July 8, 2022
2:15 pm

The FDA widened the antiviral’s emergency authorization to allow for pharmacists to write prescriptions. Not everyone is pleased.

  • From Our Partners